Insider Selling: Ionis Pharmaceuticals Inc (IONS) COO Sells 2,821 Shares of Stock

Ionis Pharmaceuticals Inc (NASDAQ:IONS) COO Brett P. Monia sold 2,821 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $51.76, for a total value of $146,014.96. Following the sale, the chief operating officer now owns 18,604 shares in the company, valued at $962,943.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ionis Pharmaceuticals Inc (IONS) opened at $51.12 on Thursday. The firm has a market cap of $6,360.00, a PE ratio of 365.14 and a beta of 2.86. Ionis Pharmaceuticals Inc has a 12 month low of $37.26 and a 12 month high of $65.51. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC purchased a new position in Ionis Pharmaceuticals in the 3rd quarter worth approximately $100,000. Parallel Advisors LLC lifted its stake in Ionis Pharmaceuticals by 60.3% in the 3rd quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock worth $182,000 after purchasing an additional 1,250 shares in the last quarter. Hanseatic Management Services Inc. lifted its stake in Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after purchasing an additional 41 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Ionis Pharmaceuticals by 9.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after purchasing an additional 311 shares in the last quarter. Finally, WFG Advisors LP lifted its stake in Ionis Pharmaceuticals by 77.2% in the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after purchasing an additional 1,655 shares in the last quarter. 91.40% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently commented on IONS shares. BidaskClub raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. Morgan Stanley raised their price target on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Barclays decreased their price target on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a research note on Thursday, September 21st. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $50.00 price target on shares of Ionis Pharmaceuticals in a research note on Friday, October 13th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $50.76.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Ionis Pharmaceuticals Inc (IONS) COO Sells 2,821 Shares of Stock” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://sportsperspectives.com/2018/01/18/insider-selling-ionis-pharmaceuticals-inc-ions-coo-sells-2821-shares-of-stock.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply